Literature DB >> 8739054

Pituitary response to early follicular-phase minidose gonadotropin releasing hormone agonist (GnRHa) therapy: evidence for a second flare.

J L Deaton1, P Bauguess, C S Huffman, K A Miller.   

Abstract

PURPOSE: Our purpose was to determine the pituitary response to minidose follicular-phase GnRHa and see if a second flare can be achieved.
METHOD: A prospective, consecutive series of 12 couples with tubal-factor infertility underwent 14 cycles of minidose GnRHa. Women were given a 25- or 50-migrograms dose of leuprolide acetate (LA) on cycle days 2 and 5. On cycle days 3 and 4 no LA was given but 2 ampoules of pure follicle stimulating hormone (FSH) was administered. Beginning day 6, a combination of LA and FSH was administered.
RESULTS: Following a dose of only 25 micrograms of LA on cycle day 2, mean FSH, LH, and E2 levels were significantly elevated over the baseline levels. Following no LA on cycle day 3 or 4, a repeat dose of 25 micrograms LA caused a second flare of LH and E2 on cycle day 6. Of the 14 cycles, 6 were canceled because of poor stimulation. Two of the eight patients who underwent retrieval delivered a live birth.
CONCLUSIONS: This is the first study to examine both the pituitary response and the recovery time from minidose follicular-phase GnRHa. An extremely small dose of LA is needed to cause a pituitary flare of gonadotropins. Following a flare from 25 micrograms of LA on cycle day 2, the pituitary is able to recover and respond with a repeat flare on cycle day 5.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8739054     DOI: 10.1007/bf02066170

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  23 in total

1.  Progesterone levels on the day of human chorionic gonadotropin administration in cycles with gonadotropin-releasing hormone agonist suppression are not predictive of pregnancy outcome.

Authors:  M C Edelstein; H J Seltman; B J Cox; S M Robinson; R A Shaw; S J Muasher
Journal:  Fertil Steril       Date:  1990-11       Impact factor: 7.329

2.  The use of a short regimen of buserelin, a gonadotrophin-releasing hormone agonist, and human menopausal gonadotrophin in assisted conception cycles.

Authors:  E J Owen; M C Davies; C R Kingsland; H S Jacobs; B A Mason
Journal:  Hum Reprod       Date:  1989-10       Impact factor: 6.918

Review 3.  Luteinizing hormone: its role, mechanism of action, and detrimental effects when hypersecreted during the follicular phase.

Authors:  Z Shoham; H S Jacobs; V Insler
Journal:  Fertil Steril       Date:  1993-06       Impact factor: 7.329

4.  Premature elevation of plasma progesterone alters pregnancy rates of in vitro fertilization and embryo transfer.

Authors:  R Fanchin; D de Ziegler; J Taieb; A Hazout; R Frydman
Journal:  Fertil Steril       Date:  1993-05       Impact factor: 7.329

5.  A randomized comparative study of purified follicle stimulating hormone and human menopausal gonadotropin after pituitary desensitization with Buserelin for superovulation and in vitro fertilization.

Authors:  B Bentick; R W Shaw; C A Iffland; G Burford; A Bernard
Journal:  Fertil Steril       Date:  1988-07       Impact factor: 7.329

6.  Elevated serum progesterone levels on the day of human chorionic gonadotropin administration do not predict outcome in assisted reproduction cycles.

Authors:  C R Givens; E D Schriock; P V Dandekar; M C Martin
Journal:  Fertil Steril       Date:  1994-11       Impact factor: 7.329

7.  The Lupron screening test: tailoring the use of leuprolide acetate in ovarian stimulation for in vitro fertilization.

Authors:  S L Padilla; R D Smith; J E Garcia
Journal:  Fertil Steril       Date:  1991-07       Impact factor: 7.329

8.  Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase.

Authors:  J D Stanger; J L Yovich
Journal:  Br J Obstet Gynaecol       Date:  1985-04

9.  Ovarian response and outcome of in-vitro fertilization in patients treated with gonadotrophin-releasing hormone analogues in different phases of the menstrual cycle.

Authors:  A Pellicer; C Simón; F Miró; R M Castellví; A Ruiz; M Ruiz; M Pérez; F Bonilla-Musoles
Journal:  Hum Reprod       Date:  1989-04       Impact factor: 6.918

10.  Value of suppression with a gonadotropin-releasing hormone agonist prior to gonadotropin stimulation for in vitro fertilization.

Authors:  K Droesch; S J Muasher; R G Brzyski; G S Jones; S Simonetti; H C Liu; Z Rosenwaks
Journal:  Fertil Steril       Date:  1989-02       Impact factor: 7.329

View more
  4 in total

Review 1.  Management of the poor responder: the role of GnRH agonists and antagonists.

Authors:  Eric S Surrey
Journal:  J Assist Reprod Genet       Date:  2007-11-29       Impact factor: 3.412

2.  Effectiveness of low dose of gonadotropin releasing hormone agonist on hormonal flare-up.

Authors:  B Bständig; I Cédrin-Durnerin; J N Hugues
Journal:  J Assist Reprod Genet       Date:  2000-02       Impact factor: 3.412

Review 3.  Different ovarian stimulation protocols for women with diminished ovarian reserve.

Authors:  D Loutradis; P Drakakis; E Vomvolaki; A Antsaklis
Journal:  J Assist Reprod Genet       Date:  2007-11-22       Impact factor: 3.412

4.  Strategies for Pituitary Down-regulation to Optimize IVF/ICSI Outcome in Poor Ovarian Responders.

Authors:  Ahmed Badawy; Alaa Wageah; Mohamed El Gharib; Ezz Eldin Osman
Journal:  J Reprod Infertil       Date:  2012-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.